Literature DB >> 32549916

Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Vamsi Reddy1, Dayton Grogan1, Meenakshi Ahluwalia2, Évila Lopes Salles3, Pankaj Ahluwalia2, Hesam Khodadadi3, Katelyn Alverson1, Andy Nguyen1, Srikrishnan P Raju1,4, Pankaj Gaur5,6, Molly Braun1,7,8, Fernando L Vale1, Vincenzo Costigliola9, Krishnan Dhandapani1, Babak Baban3, Kumar Vaibhav1.   

Abstract

Cannabis-inspired medical products are garnering increasing attention from the scientific community, general public, and health policy makers. A plethora of scientific literature demonstrates intricate engagement of the endocannabinoid system with human immunology, psychology, developmental processes, neuronal plasticity, signal transduction, and metabolic regulation. Despite the therapeutic potential, the adverse psychoactive effects and historical stigma, cannabinoids have limited widespread clinical application. Therefore, it is plausible to weigh carefully the beneficial effects of cannabinoids against the potential adverse impacts for every individual. This is where the concept of "personalized medicine" as a promising approach for disease prediction and prevention may take into the account. The goal of this review is to provide an outline of the endocannabinoid system, including endocannabinoid metabolizing pathways, and will progress to a more in-depth discussion of the therapeutic interventions by endocannabinoids in various neurological disorders. © European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2020.

Entities:  

Keywords:  2-Arachidonyl glycerol; Alzheimer’s disease; Amyloid lateral sclerosis; Anandamide; Anxiety; Cancer; Cannabinoid receptor; Depression; Disease management; Endocannabinoid system; Epilepsy; Health policy; Huntington’s disease; Multi-professional expertise; Multiple sclerosis; Neurological disorder; Pain; Parkinson’s disease; Predictive preventive personalized medicine (PPPM); Schizophrenia; Stroke; Therapeutic strategies; Traumatic brain injury

Year:  2020        PMID: 32549916      PMCID: PMC7272537          DOI: 10.1007/s13167-020-00203-4

Source DB:  PubMed          Journal:  EPMA J        ISSN: 1878-5077            Impact factor:   6.543


  501 in total

Review 1.  Cannabinoid signaling in glioma cells.

Authors:  Aleksandra Ellert-Miklaszewska; Iwona Ciechomska; Bozena Kaminska
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

2.  A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease.

Authors:  Justin R Piro; Daniel I Benjamin; James M Duerr; YeQing Pi; Cathleen Gonzales; Kathleen M Wood; Joel W Schwartz; Daniel K Nomura; Tarek A Samad
Journal:  Cell Rep       Date:  2012-06-21       Impact factor: 9.423

3.  Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.

Authors:  I Lastres-Becker; M Cebeira; M L de Ceballos; B Y Zeng; P Jenner; J A Ramos; J J Fernández-Ruiz
Journal:  Eur J Neurosci       Date:  2001-12       Impact factor: 3.386

4.  Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons.

Authors:  W Twitchell; S Brown; K Mackie
Journal:  J Neurophysiol       Date:  1997-07       Impact factor: 2.714

Review 5.  Risks associated with the stroke predisposition at young age: facts and hypotheses in light of individualized predictive and preventive approach.

Authors:  Jiri Polivka; Jiri Polivka; Martin Pesta; Vladimir Rohan; Libuse Celedova; Smit Mahajani; Ondrej Topolcan; Olga Golubnitschaja
Journal:  EPMA J       Date:  2019-02-20       Impact factor: 6.543

6.  Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  A A Martinez; M G Morgese; A Pisanu; T Macheda; M A Paquette; A Seillier; T Cassano; A R Carta; A Giuffrida
Journal:  Neurobiol Dis       Date:  2014-12-05       Impact factor: 5.996

7.  Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury.

Authors:  Paige S Katz; Jesse K Sulzer; Renata A Impastato; Sophie X Teng; Emily K Rogers; Patricia E Molina
Journal:  J Neurotrauma       Date:  2014-12-19       Impact factor: 5.269

8.  Differential expression and functional role of cannabinoid genes in alcohol users.

Authors:  Marisela Agudelo; Adriana Yndart; Marisol Morrison; Gloria Figueroa; Karla Muñoz; Thangavel Samikkannu; Madhavan P Nair
Journal:  Drug Alcohol Depend       Date:  2013-09-05       Impact factor: 4.492

Review 9.  A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics.

Authors:  Melissa E Badowski
Journal:  Cancer Chemother Pharmacol       Date:  2017-08-05       Impact factor: 3.333

10.  Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis.

Authors:  Jing Wang; Yanling Wang; Mengting Tong; Hongming Pan; Da Li
Journal:  Biomed Res Int       Date:  2019-06-23       Impact factor: 3.411

View more
  9 in total

Review 1.  Inflammaging and Cannabinoids.

Authors:  Babak Baban; Hesam Khodadadi; Évila Lopes Salles; Vincenzo Costigliola; John C Morgan; David C Hess; Kumar Vaibhav; Krishnan M Dhandapani; Jack C Yu
Journal:  Ageing Res Rev       Date:  2021-10-15       Impact factor: 10.895

2.  The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders.

Authors:  Qing Xin; Fei Xu; Devin H Taylor; Jing-Fu Zhao; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2020-10-06       Impact factor: 6.150

Review 3.  Rescuing mitochondria in traumatic brain injury and intracerebral hemorrhages - A potential therapeutic approach.

Authors:  Meenakshi Ahluwalia; Manish Kumar; Pankaj Ahluwalia; Scott Rahimi; John R Vender; Raghavan P Raju; David C Hess; Babak Baban; Fernando L Vale; Krishnan M Dhandapani; Kumar Vaibhav
Journal:  Neurochem Int       Date:  2021-09-22       Impact factor: 3.921

4.  Involvement of CB2 signalling pathway in the development of osteoporosis by regulating the proliferation and differentiation of hBMSCs.

Authors:  Feng Tian; Hong-Tao Yang; Tao Huang; Feng-Feng Chen; Fu-Jun Xiong
Journal:  J Cell Mol Med       Date:  2021-01-29       Impact factor: 5.310

5.  Hair cortisol level might be indicative for a 3PM approach towards suicide risk assessment in depression: comparative analysis of mentally stable and depressed individuals versus individuals after completing suicide.

Authors:  Alexander Karabatsiakis; Karin de Punder; Juan Salinas-Manrique; Melanie Todt; Detlef E Dietrich
Journal:  EPMA J       Date:  2022-08-30       Impact factor: 8.836

Review 6.  Revisiting Traumatic Brain Injury: From Molecular Mechanisms to Therapeutic Interventions.

Authors:  Abbas Jarrahi; Molly Braun; Meenakshi Ahluwalia; Rohan V Gupta; Michael Wilson; Stephanie Munie; Pankaj Ahluwalia; John R Vender; Fernando L Vale; Krishnan M Dhandapani; Kumar Vaibhav
Journal:  Biomedicines       Date:  2020-09-29

Review 7.  Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.

Authors:  Dhanush Haspula; Michelle A Clark
Journal:  Int J Mol Sci       Date:  2020-10-17       Impact factor: 5.923

Review 8.  Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions.

Authors:  Tapan Behl; Gagandeep Kaur; Simona Bungau; Rishabh Jhanji; Arun Kumar; Vineet Mehta; Gokhan Zengin; Roxana Brata; Syed Shams Ul Hassan; Ovidiu Fratila
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

9.  Association of Serum Complement C1q and C3 Level with Age-Related Macular Degeneration in Women.

Authors:  Yingbo Ma; Xueqing Ding; Mingxi Shao; Yichao Qiu; Shengjie Li; Wenjun Cao; Gezhi Xu
Journal:  J Inflamm Res       Date:  2022-01-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.